Tilray Brands shares gain as analysts boost price target on cannabis rescheduling optimism

Tilray Brands (TLRY) shares gained 4.2% on Tuesday, extending a 36% five-day rally, after Jefferies analysts raised their price target from $1.50 to $2 while maintaining a 'Buy' rating. This upgrade reflects growing optimism regarding the potential federal rescheduling of cannabis from Schedule I to Schedule III, which could significantly benefit cannabis companies like Tilray through reduced tax burdens and easier research access. Jefferies identifies Tilray as a primary beneficiary of this regulatory shift, citing its brand strength, scale, and balance sheet.

Analysis

Tilray Brands (TLRY) is experiencing significant positive momentum, with its shares gaining 4.2% to $1.45, extending a five-day rally of over 36%. This surge is directly linked to a favorable analyst action from Jefferies, which maintained a 'Buy' rating while raising its price target to $2.00 from a previous $1.50. The core catalyst for this bullish revision is growing optimism around the potential federal rescheduling of cannabis from a Schedule I to a Schedule III substance in the United States. Jefferies notes that while this is “not legalization, but progress,” the shift would provide considerable benefits, including lower tax burdens and easier research access. The analysts specifically identify Tilray as potentially the “largest beneficiary” of this regulatory change, citing its superior brand strength, operational scale, and balance sheet as key assets to capture the emerging opportunity.

Key Decisions for Investors

• Given the Jefferies price target of $2.00 and Tilray's positioning as a prime beneficiary of policy change, investors with a high-risk tolerance may consider the stock a speculative buy on regulatory momentum.
• The investment thesis is heavily dependent on a potential, not guaranteed, regulatory shift; therefore, investors must closely monitor official news on cannabis rescheduling, as any delay or failure to pass would likely trigger a sharp reversal of the recent 36% gain.
• Considering the rapid run-up in the share price over the last five trading days, it is prudent to be cautious of near-term volatility and the possibility of a price correction as early speculators take profits.